Zentiva étend son activité aux produits biologiques avec le lancement de son premier biosimilaire dans l'UE

Core Insights - Zentiva has launched its first monoclonal antibody biosimilar in Europe, marking a strategic entry into the biosimilars market and enhancing patient access to high-quality biological medicines across Europe [1][2][3] Group 1: Company Strategy - The launch represents a significant step for Zentiva in the field of biological medicines, aligning with its mission to make high-quality treatments more accessible and affordable for European citizens [2] - This expansion positions Zentiva for sustainable growth in one of the most dynamic segments of the pharmaceutical industry, as biosimilars are essential for ensuring the viability of healthcare systems and patient access to modern therapies [3] Group 2: Product Details - The newly launched biosimilar is a monoclonal antibody used for treating bone conditions, approved through the centralized procedure of the European Medicines Agency (EMA) [2] - The biosimilar will gradually become available in European markets starting in December 2025 [2] Group 3: Company Overview - Zentiva focuses on the development, production, and distribution of high-quality, affordable medicines for over 100 million people in more than 30 countries across Europe and beyond [4] - The company operates four wholly-owned production sites and has a broad network of external manufacturing partners to ensure supply security, employing over 5,000 individuals committed to patient health [4]